1. Home
  2. LOAN vs IFRX Comparison

LOAN vs IFRX Comparison

Compare LOAN & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LOAN
  • IFRX
  • Stock Information
  • Founded
  • LOAN 1989
  • IFRX 2007
  • Country
  • LOAN United States
  • IFRX Germany
  • Employees
  • LOAN N/A
  • IFRX N/A
  • Industry
  • LOAN Real Estate Investment Trusts
  • IFRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LOAN Real Estate
  • IFRX Health Care
  • Exchange
  • LOAN Nasdaq
  • IFRX Nasdaq
  • Market Cap
  • LOAN 61.5M
  • IFRX 53.5M
  • IPO Year
  • LOAN 1999
  • IFRX 2017
  • Fundamental
  • Price
  • LOAN $5.37
  • IFRX $1.18
  • Analyst Decision
  • LOAN
  • IFRX Strong Buy
  • Analyst Count
  • LOAN 0
  • IFRX 5
  • Target Price
  • LOAN N/A
  • IFRX $7.40
  • AVG Volume (30 Days)
  • LOAN 21.2K
  • IFRX 1.0M
  • Earning Date
  • LOAN 10-22-2025
  • IFRX 11-07-2025
  • Dividend Yield
  • LOAN 8.60%
  • IFRX N/A
  • EPS Growth
  • LOAN N/A
  • IFRX N/A
  • EPS
  • LOAN 0.48
  • IFRX N/A
  • Revenue
  • LOAN $7,300,469.00
  • IFRX $191,224.00
  • Revenue This Year
  • LOAN N/A
  • IFRX N/A
  • Revenue Next Year
  • LOAN $4.47
  • IFRX $1,216.24
  • P/E Ratio
  • LOAN $11.15
  • IFRX N/A
  • Revenue Growth
  • LOAN N/A
  • IFRX 54.36
  • 52 Week Low
  • LOAN $4.74
  • IFRX $0.71
  • 52 Week High
  • LOAN $6.05
  • IFRX $2.82
  • Technical
  • Relative Strength Index (RSI)
  • LOAN 49.82
  • IFRX 47.44
  • Support Level
  • LOAN $5.28
  • IFRX $1.09
  • Resistance Level
  • LOAN $5.44
  • IFRX $1.77
  • Average True Range (ATR)
  • LOAN 0.11
  • IFRX 0.21
  • MACD
  • LOAN 0.00
  • IFRX -0.05
  • Stochastic Oscillator
  • LOAN 75.00
  • IFRX 24.26

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: